

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: March 28, 2007

By: /s/ Stuart M. Essig

Stuart M. Essig
President and Chief Executive Officer

Exhibit Index

| Exhibit Number | Description of Exhibit |
|----------------|-------------------------------------|
| ----- | ----- |
| 99.1 | Press release issued March 23, 2007 |

Contacts:

Integra LifeSciences Holdings Corporation

John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com

John Bostjancic
Vice President, Corporate Development
and Investor Relations
(609) 936-2239
jbostjancic@Integra-LS.com

Integra LifeSciences Announces Agreement to Acquire
LXU Healthcare, Inc.

Plainsboro, New Jersey / March 23, 2007/ -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced today that it has agreed to acquire LXU Healthcare, Inc. (LXU) for \$30 million in cash, subject to certain adjustments. LXU employs approximately 140 employees. After closing, LXU will be operated as part of Integra's Jarit Surgical Instruments business activities.

LXU, based in West Boylston, Massachusetts, is comprised of 3 distinct businesses:

- o Luxtec - The market-leading manufacturer of fiber optic headlight systems for the medical industry through its Luxtec(R) brand. Luxtec's headlight systems are used by over 50,000 surgeons worldwide and are the vision systems of choice for training in hospitals and medical schools. A surgical headlight system consists of three main components: a light source or generator, a flexible fiber optic cable, and a surgical headlight. Luxtec's flagship products include the UltraLite(R) and UltraLux(R) Xenon fiber optic surgical headlights. These ergonomic and lightweight headlights aim a bright, white light in line with the surgeon's visual focus providing better direct illumination of the surgical site. The Luxtec products are manufactured in a 31,000 square foot leased facility located in West Boylston.
- o LXU Medical - A leading specialty surgical products distributor with a technically proficient sales force calling on surgeons and key clinical decision makers, covering 18,000 operating rooms in the southeastern, midwestern and mid-Atlantic United States. LXU Medical is the exclusive distributor of the Luxtec fiber optic headlight systems in these territories.
- o Bimeco - A critical care products distributor with direct sales coverage in the southeastern US.

The transaction offers a number of strategic benefits to Integra LifeSciences:

- o The Luxtec brand of surgical headlight systems will provide the Jarit sales organization with increased exposure and growth opportunities in the hospital and ambulatory surgery center market. Approximately 40% of Luxtec products are used by cardiovascular surgeons, 20% by general surgeons, 10% by neurosurgeons and 7% each by ENT and orthopedic surgeons.
- o Provides increased access to specialty surgeons and allows us to position Jarit's growing lines of specialty surgical instrumentation directly to the end-user. Additionally, the combination of Luxtec light sources and Jarit(R) surgical retraction systems will provide our customers with outstanding operative-site illumination and visibility.
- o Increases Integra's global product offering and international market presence with the addition of proprietary light source systems used regularly by specialty surgeons around the world.
- o Adds a technically proficient sales force that serves the southeastern, midwestern and mid-Atlantic United States with specialized, distributed medical products covering over 18,000 operating rooms.
- o Increases Integra's global, market leading neurosurgery product offering with the addition of proprietary light source systems used regularly by neurosurgeons.
- o Enhances the efficiencies of Integra's global infrastructure and distribution network through economies of scale and cost synergies.

"This acquisition represents an excellent strategic fit for Integra LifeSciences. It provides significant growth opportunities for the Jarit and LXU Medical sales teams by leveraging our combined strength and exposure of leading brand names within the surgical community," said Stuart M. Essig, Integra's President and Chief Executive Officer.

Luxtec sells its products in 60 countries, using a network of independent distributors in the United States and internationally. Many Luxtec distributors already sell Jarit(R) surgical instrument products.

"The Luxtec headlight systems will also strengthen Integra's product offering in general surgery, providing an exceptional complement to the portfolio of products already offered by our Jarit sales organization," Mr. Essig added. "We have great respect for the LXU management team who have built the Luxtec and specialty distribution business and look forward to joining forces as we expand our presence into various surgical disciplines with clinically relevant products and services."

"The Luxtec surgical headlight system is a necessary and well-regarded product-line" adds Rob Rogowski, President of Jarit Surgical Instruments. "It will provide us with a unique entree to specialty surgeons, allowing us to highlight Jarit's growing lines of surgical instrumentation directly to the end-user. Also, there is a natural opportunity to combine Luxtec light sources with Jarit(R) surgical retraction systems to provide our customers with a comprehensive and compatible package of operative-site illumination."

"We are delighted to join Integra and look forward to working with the Integra team to contribute to our companies' mutual growth," said Joe Potenza, President and Chief Executive Officer of LXU Healthcare.

For the year ended December 31, 2006, LXU Healthcare generated revenues of \$49.4 million and earnings before interest, taxes, depreciation and amortization (EBITDA) of \$2.6 million. Integra expects to divest or discontinue certain products of LXU which are not core to its business. Accordingly, under Integra's ownership, we expect LXU Healthcare to generate approximately \$30 million of revenue on an annual basis in the first year after the completion of the integration.

Additionally, by the end of 2007, Integra expects to integrate LXU Medical's administrative and distribution operations into Integra's existing infrastructure and generate cost savings.

Upon the closing of the transaction, Integra will provide more detailed guidance regarding the financial aspects of the transaction and its expected impact on Integra's future financial results.

Completion of the transaction is subject to customary closing conditions. We expect the transaction to close early in the second quarter.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products are used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

LXU Healthcare, Inc. is a specialty medical products sales, marketing and manufacturing company. Based in Massachusetts, the Company sells a broad portfolio of specialty medical products, to over 3,000 hospitals and surgery centers nationwide through its LXU Medical division. For more information about LXU Healthcare, please visit <http://www.lxuhc.com/>

Burnham Securities Inc. (New York, NY), representing LXU Healthcare, originated the transaction.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the closing of this transaction and expectations for this newly acquired business and the expected impact of this acquisition on Integra's future financial results. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, Integra's ability to successfully close this transaction on the terms contemplated and integrate the LXU Healthcare product lines into its operations could affect the impact of this acquisition on Integra's future financial results. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2006 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation